Sumatriptan Needle-Free Injection for Migraine Discontinued

This article originally appeared here.
Share this content:
The decision to discontinue Sumavel DosePro is not related to the product's quality, safety or efficacy.
The decision to discontinue Sumavel DosePro is not related to the product's quality, safety or efficacy.

Endo has made a business decision to discontinue Sumavel DosePro (sumatriptan injection) 6mg/0.5mL. 

Sumavel DosePro was approved in 2009 for the acute treatment of migraine or cluster headaches as a needle-free delivery system supplied in prefilled pens. The 4mg/0.5mL formulation was previously discontinued in 2016; today's decision affecting the 6mg/0.5mL formulation is also not related to the product's quality, safety or efficacy.

Sumatriptan, a selective 5-HT1B/1D receptor agonist, presumably exerts therapeutic effects by binding to 5-HT1B/1D receptors located on intracranial blood vessels an sensory nerves of the trigeminal system.

The agonist effects are thought to result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Follow @ClinicalPainAdv

Reference

FDA drug shortages. Current and resolved drug shortages and discontinuations reported to FDA. FDA. Updated February 27, 2018. Accessed March 6, 2018.

You must be a registered member of Clinical Pain Advisor to post a comment.